COMPANY

Cambium Oncology LLC

HQ: Atlanta, GA source · cambiumoncology.com ↗ · Southeast

Keywords: oncology

Location: Atlanta, GA · source · Oct 15, 2026

Profile checked Oct 10, 2026

NIH awards 4

Annual award amounts. Total $2.9M.

Jul 17, 2026 NIH award 5R44CA285206-03 FY2026: $1,050,003 awarded for that fiscal year; activity R44 (SBIR); PI ALTMAN, GARY G.; recipient as written: CAMBIUM ONCOLOGY LLC, ATLANTA, GA. Development of a Novel Immunotherapeutic fo source ↗
Sep 9, 2025 NIH award 4R44CA285206-02 FY2025: $999,997 awarded for that fiscal year; activity R44 (SBIR); PI ALTMAN, GARY G.; recipient as written: CAMBIUM ONCOLOGY LLC, ATLANTA, GA. Development of a Novel Immunotherapeutic for source ↗
Apr 23, 2025 NIH award 1R44CA298704-01 FY2025: $400,835 awarded for that fiscal year; activity R44 (SBIR); PI ALTMAN, GARY G.; recipient as written: CAMBIUM ONCOLOGY LLC, ATLANTA, GA. Development of a Novel Armored CAR-T Immunoth source ↗
Jun 12, 2024 NIH award 1R44CA285206-01A1 FY2024: $404,995 awarded for that fiscal year; activity R44 (SBIR); PI ALTMAN, GARY G.; recipient as written: CAMBIUM ONCOLOGY LLC, ATLANTA, GA. Development of a Novel Immunotherapeutic fo source ↗

NIH award NIH awarded $1.05M (SBIR Phase II 5R44CA285206-03, continuation, notice Jul 17, 2026). NIH RePORTER 5R44CA285206-03 (Jul 17, 2026)
Evidence (1 event)
- Jul 17, 2026 · NIH RePORTER 5R44CA285206-03
  Organization: CAMBIUM ONCOLOGY LLC; City/State: ATLANTA, GA; Project number: 5R44CA285206-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-17; FY total cost (award amount): 1050003; Administering IC: National Cancer Institute; Project title: Development of a Novel Immunotherapeutic for Acute Myeloid Leukemia; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals